Endo International plc (NASDAQ: ENDP), a specialty pharmaceutical company, announced on Wednesday that it has named Jennifer M Chao as its director effective immediately.

Chao has more than 25 years of experience in the biotech and life sciences industries. She is the founder of CoreStrategies Management LLC. She has also held the position of chairman of the board of BioSpecifics Technologies Corporation. She has served as managing director and senior lead biotechnology securities analyst at Deutsche Bank. She has held the position of a managing director and senior lead biotechnology analyst at RBC Capital Markets and a senior analyst in Biotechnology at Leerink Swann & Co.

Paul Campanelli, Endo's chairman of the board, said, 'We are pleased to welcome Jennifer to the Endo Board. Jennifer's deep experience in pharmaceuticals and biotechnology along with her strong financial acumen should be invaluable to Endo as we continue our mission to develop and deliver life enhancing products.'